Clinical Trial Update: Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma [Phase 2]

View source ↗

Summary

Phase 2 trial of LMB-100 followed by pembrolizumab in malignant mesothelioma was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Mesothelioma

Drugs mentioned

• LMB-100 (mesothelin-targeted immunotoxin)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Mesothelioma | Phase 2 | Status: TERMINATED | Results posted: 2021-12-02